DIJON, France--(BUSINESS WIRE)--Regulatory News:
ONCODESIGN (Paris:ALONC) (FR0011766229 - ALONC), a biotechnology company serving the pharmaceutical industry in the discovery of new therapeutic molecules to fight cancer and other serious illnesses with no known efficient treatment, announces the creation of its Scientific Advisory Board which includes 6 renowned scientists and clinicians. The Scientific Advisory Board will provide high-level advisory support, recommendations for the discovery programmes on next-generation kinase inhibitors based on the Nanocyclix technology, and strategic options involving Oncodesign technologies.
Help employers find you! Check out all the jobs and post your resume.
